A Solution for Overcrowded Emergency Departments for Patient with Symptoms of Heart Attack
Interactive Media Kit
Why cardiac testing matters in 2022: Facts and figures
17.7 million people die every year from Cardiovascular Diseases, an estimated 31% of all deaths worldwide.2
Cardiovascular disease is the #1 cause of death globally.1
When a patient presents with symptoms of a potential heart attack, they and their families depend on everyone working together with speed and confidence for favorable outcomes. During those most critical moments, trust, time, and resources aren't just valuable—they're vital. Fast and accurate diagnosis can make all the difference to patients waiting to find out if they've had a heart attack.
Every minute waiting on test results comes at a cost when patients present to the emergency department with signs and symptoms that may indicate myocardial infarction (MI).
Patients and their families are anxious, and clinicians and laboratory professionals are pressured to identify the problem quickly and accurately. Fear and anxiety are common emotions for anyone with heart conditions, and an acute onset of chest pain or other symptoms requiring emergency evaluation can exacerbate those feelings.3
Heart disease has remained the leading cause of death at the global level for the last 20 years.5
A patient safety issue and worldwide public health problem
Many emergency departments today are overcrowded, leaving both patients and providers waiting for answers. How can this be improved? How can we increase efficiency and diagnostic confidence for clinicians?
Expediting triage times for patients presenting with heart attack symptoms enhances patient care and helps against Emergency Department overcrowding—a patient safety issue and a worldwide public health problem that contributes to cardiac deaths.4
Having high-sensitivity troponin I testing available at the bedside can transform the way chest pain patients are assessed, providing reliable results in just 8 minutes.
A vital leap forward in cardiac testing
Transforming Care Delivery with Atellica VTLi Analyzer
The Atellica® VTLi Patient-side Immunoassay Analyzer, a high-sensitivity troponin I test at the bedside, delivers accurate results in just 8 minutes. By improving patient wait times and accuracy, the analyzer could transform care delivery for millions of patients each year. When clinicians can get high-sensitivity cardiac troponin results at the speed of care, emergency department patient wait times may be improved, aiding in earlier diagnosis for patients having a heart attack and peace of mind for those who are not.
The Atellica VTLi Patient-side Immunoassay Analyzer can be used in emergency settings with patients presenting with symptoms of a heart attack.
Benefitting physicians and patients
Optimized Emergency Department Wait Times
Streamlines chest pain assessment, aiding in earlier diagnosis for patients having a heart attack and peace of mind for those who are not.
Evidence-Based, Accurate Results
Offers high-sensitivity Troponin I testing right at the bedside. Results are available in just minutes for patients, clinicians and laboratory partners.
Easily Integrated into Assessment Process
Transforms the chest pain assessment process to benefit patients and clinicians.
Videos: Expert perspectives
Dr. Paul Collinson is a professor of Cardiovascular Biomarkers and Former Consultant in Chemical Pathology at St George’s University Hospital
“With the Atellica VTLi system, we’re able to improve the patient pathway by combining rapid results with a process redesigned with the use of an ambulatory care area. We can use space more efficiently, and more importantly, we're going to get them out of hospital faster.”
DR. PAUL COLLINSON
What do respected clinicians have to say about Atellica VTLi Analyzer?
Media Materials
This image is a preview. The complete infographic is available for download and may be republished with proper attribution (Graphic courtesy of Siemens Healthineers. ©2022 Siemens Healthcare Diagnostics Inc.).
Infographic & Press Release
Once a patient develops symptoms and seeks care at a hospital, their patient pathway begins. At that point, every minute counts.
Make this infographic available to your readers to help them understand the cardiac clinical pathway. If you republish, please provide proper attribution:
Graphic courtesy of Siemens Healthineers. ©2022 Siemens Healthcare Diagnostics Inc.
Images available for the media
Attribution: Image courtesy of Siemens Healthineers. ©2022 Siemens Healthcare Diagnostics Inc.
The Atellica VTLi Patient-side Immunoassay Analyzer delivers high-sensitivity troponin I results at the patient-side in 8 minutes.
The Atellica VTLi high-sensitivity troponin I reagent cartridge contains an RFID chip that contains expiry and lot specific data.
The Atellica VTLi hs-cTnI reagent cartridge contains an RFID chip that contains expiry and lot specific data.
Important Dates
Press Contact: Kimberly Nissen
Siemens Medical Solutions, Inc, 40 Liberty Boulevard, Malvern, PA, 19355
References
- Utility of the History of Physical Examination in the Detection of Acute Coronary Syndromes in Emergency Department Patients. Western Journal of Emergency Medicine. Volume 18, no. 4: June 2017. DOI: 10.5811/westje.2017.3.32666
- Screening of family members of pts. w/premature CAD, EUROASPIRE I- EHJ (2003);24: 249-257.
- Heart conditions and mental health. British Heart Foundation. https://www.bhf.org.uk/informationsupport/heart-matters-magazine/wellbeing/mental-health/mental-health-survey
- What we have learned from a decade of ED crowding research. Pines, JM, Griffey RT, Acad Emerg Med. 2015 Aug;22(8):985-7. doi: 10.1111/acem.12716. Epub 2015 Jul 20
WHO reveals leading causes of death and disability worldwide: 2000-2019. World Health Organization, Pan American Health Organization. Epub 2020 Dec 9. https://www.paho.org/en/news/9-12-2020-who-reveals-leading-causes-death-and-disability-worldwide-2000-2019
Did this information help you?
Atellica, and all associated marks are trademarks of Siemens Healthcare Diagnostics Inc., or its affiliates. All other trademarks and brands are the property of their respective owners.
Not available for sale in the U.S. The products/features (mentioned herein) are not commercially available in all countries. Their future availability cannot be guaranteed.